A Phase 2 interventional study of Niclosamide and Placebo in Covid19, sponsored by Entero Therapeutics. Terminated at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Entero Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 520th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 1,099th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Entero Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Entero Therapeutics has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Niclosamide tablets 400 mg 3 times daily for 14 days
Drug: Niclosamide
Matching placebo tablets 3 times daily for 14 days
Drug: Placebo
Niclosamide tablets 400 mg 3 times daily for 14 days
Matched placebo tablets 400 mg 3 times daily for 14 days
SAEs
Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: Day 1 to 6 weeks
TEAE
Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation.
Time frame: Day 1 to 6 weeks
Fecal RNA Virus Clearance
Time to fecal viral RNA clearance (stool sample) assessed by RT-qPCR in the niclosamide arm compared to the placebo arm.
Time frame: Day 1 to 6 weeks
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Leukocytes and Platelets)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Erythrocytes
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemocrit (L/L)
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemoglobin (g/L)
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Corpuscular volume (fL)
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically BUN, Glucose, Chloride, Potassium, and Sodium)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Alkaline Phosphatase, AST, ALT, and LDH)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
Time frame: Day 1 to Day 43
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Bilirubin and Serum Creatinine)
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
Time frame: Day 1 to Day 43
| Milestone | Niclosamide | Placebo |
|---|---|---|
| Started | 84 | 82 |
| Completed | 74 | 77 |
| Not completed | 10 | 5 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).
| participants | Niclosamide | Placebo |
|---|---|---|
| Infections and infestations | 0 | 1 |
| Injury, poisoning and procedural complications | 0 | 1 |
Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation.
| participants | Niclosamide | Placebo |
|---|---|---|
| Gastrointetinal disorders | 1 | 1 |
| Blood and lymphatic system disorders | 0 | 1 |
| Endocrine disorders | 0 | 1 |
| Infections and infestations | 0 | 1 |
| Injury, poisoning and procedural complications | 0 | 1 |
| Investigations | 1 | 1 |
| Musculoskeletal and connective tissue disorders | 0 | 1 |
Time to fecal viral RNA clearance (stool sample) assessed by RT-qPCR in the niclosamide arm compared to the placebo arm.
| participants | Niclosamide | Placebo |
|---|---|---|
| Day 4 | 8 | 9 |
| Day 8 | 21 | 20 |
| Day 15 | 40 | 33 |
| Day 22 | 48 | 42 |
| Day 29 | 51 | 43 |
| Day 36 | 51 | 45 |
| Day 43 | 52 | 48 |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
| cells (10^9/L) | Niclosamide | Placebo |
|---|---|---|
| Leukocytes | 0.340 (-12.71 to 4.38) | 0.495 (-11.13 to 5.70) |
| Platelets | 11.5 (-196 to 116) | 3.0 (-337 to 148) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Erythrocytes
| cells 10^12/L | Niclosamide | Placebo |
|---|---|---|
| Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes) | -0.250 (-0.87 to .85) | -0.125 (-0.96 to 0.84) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemocrit (L/L)
| L/L | Niclosamide | Placebo |
|---|---|---|
| Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit) | -0.0195 (-0.100 to 0.077) | -0.0130 (-0.141 to 0.072) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemoglobin (g/L)
| g/L | Niclosamide | Placebo |
|---|---|---|
| Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin) | -4.0 (-30 to 13) | -2.5 (-39 to 14) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Corpuscular volume (fL)
| fL | Niclosamide | Placebo |
|---|---|---|
| Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume) | -0.35 (-10.5 to 9.3) | -0.75 (-16.1 to 15.8) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
| mmol/L | Niclosamide | Placebo |
|---|---|---|
| BUN | 0.000 (-6.07 to 4.65) | 0.000 (-8.21 to 3.21) |
| Glucose | -0.360 (-5.22 to 3.28) | 0.110 (-9.15 to 3.28) |
| Chloride | 2.0 (-7 to 9) | 1.0 (-9 to 13) |
| Potassium | 0.00 (-1.0 to 1.1) | 0.10 (-1.9 to 2.1) |
| Sodium | 1.0 (-6 to 7) | 0.0 (-13 to 7) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
| U/L | Niclosamide | Placebo |
|---|---|---|
| Alkaline Phosphatase | 2.0 (-173 to 26) | 2.0 (-76 to 49) |
| AST | -2.5 (-117 to 98) | -1.0 (-151 to 26) |
| ALT | -3.0 (-70 to 73) | -4.0 (-77 to 32) |
| LDH | -2.0 (-209 to 157) | 6.0 (-86 to 102) |
Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.
| mcmol/L | Niclosamide | Placebo |
|---|---|---|
| Bilirubin | 0.60 (-10.7 to 10.1) | 1.20 (-4.3 to 22) |
| Creatinine | 0.0 (-53 to 44) | 0.0 (-44 to 27) |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niclosamide | 0/84 (0%) | 0/84 (0%) | 1/84 (1.2%) |
| Placebo | 0/82 (0%) | 2/82 (2.4%) | 1/82 (1.2%) |
| Event | Niclosamide | Placebo |
|---|---|---|
| Infections and infestationsInfections and infestations | 0/84 | 1/82 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 0/84 | 1/82 |
| Event | Niclosamide | Placebo |
|---|---|---|
| Gastrointestinal disordersGastrointestinal disorders | 1/84 | 1/82 |
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 0/84 | 1/82 |
| Endocrine disordersEndocrine disorders | 0/84 | 1/82 |
| Infections and infestationsInfections and infestations | 0/84 | 1/82 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 0/84 | 1/82 |
| InvestigationsInvestigations | 1/84 | 1/82 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 0/84 | 1/82 |
| Age, Categorical(Participants) | Niclosamide | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 77 | 74 | 151 |
| >=65 years | 7 | 8 | 15 |
| Sex: Female, Male(Participants) | Niclosamide | Placebo | Total |
|---|---|---|---|
| Female | 47 | 46 | 93 |
| Male | 37 | 36 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Niclosamide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 55 | 63 | 118 |
| Not Hispanic or Latino | 29 | 19 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Niclosamide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 5 | 13 |
| Native Hawaiian or Other Pacific Islander | 4 | 3 | 7 |
| Black or African American | 0 | 0 | 0 |
| White | 71 | 74 | 145 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Jun 2022, 13 months.
Results were first posted in Jul 2024, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niclosamide
Entero Therapeutics